The AHA commented Sept. 15 on the Centers for Medicare & Medicaid Services calendar year 2026 outpatient prospective payment system and ambulatory surgical center payment system proposed rule. The AHA expressed support for several policies in the rule, including direct supervision requirements for certain cardiac rehabilitation services and removing four measures from the Outpatient Quality Reporting program that were recently finalized for removal from the Inpatient Quality Reporting Program, along with the proposal to offer time extensions for data reporting for facilities experiencing an extraordinary circumstance. Provisions the AHA opposed include reducing payment for all drug administration services furnished in off-campus hospital provider-based departments to the “physician fee schedule-equivalent” rate of 40% of the OPPS payment amount, eliminating the inpatient-only list over three years, weakening the ASC Covered Procedures List standard criteria and general exclusion criteria and accelerating the timeline for clawing back funds from CMS' unlawful policy between CY 2018 and 2022 that harmed certain hospitals participating in the 340B Drug Pricing Program.

Related News Articles

Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.  “When…
Blog
Public
Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4…
Headline
The AHA, the Maine Hospital Association and four safety-net health systems from across the country Dec. 1 filed a lawsuit in the U.S. District…
Chairperson's File
Public
For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription…
Headline
The Centers for Medicare & Medicaid Services Nov. 21 issued a final rule that, among other provisions, increases Medicare hospital outpatient prospective…
Chairperson's File
Public
In last month’s Chair File, we talked about some of the key priorities the AHA has for the remainder of 2025, one of which is protecting the 340B Drug Pricing…